Atlas Trials

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Clinical trial NCT06388759 · TERMINATED

Trial details

NCT number
NCT06388759
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Myelofibrosis
Start date
2022-08-01
Primary completion
2025-08-12
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.